Yolt-202 therapy corrects serpina1 gene in Alpha-1 Antitrypsin Deficiency patient
A 66-year-old patient has shown molecular correction of the SERPINA1 gene following a single intravenous infusion of YOLT-202, an adenine base editor developed by YolTech Therapeutics. Reported in the Journal of Hepatology on November 1, 2026, the clinical data confirms that the base-editing therapy successfully converted the pathogenic adenine to guanine in vivo, addressing the underlying cause of Alpha-1 Antitrypsin Deficiency (AATD).
- Serum Alpha-1 Antitrypsin (AAT) levels rose from 0.15 g/L to 0.70 g/L within ten weeks, surpassing the 0.57 g/L therapeutic threshold.
- The adenine base editor achieved correction without inducing DNA double-strand breaks, reducing the risk of unintended chromosomal rearrangements.
- Liver biopsies confirmed the production of functional AAT protein, though long-term safety and clinical durability remain under investigation.
Gene Editing Therapy Restores Normal Protein Levels
The Z variant of the SERPINA1 gene causes a misfolding of AAT proteins, leading to their accumulation within hepatocytes—the primary functional cells of the liver—and a concomitant reduction in circulating AAT levels. The YOLT-202 treatment utilizes lipid nanoparticle-formulated adenine base editors to convert the pathogenic adenine back to guanine to address the Z variant of SERPINA1. By precisely targeting the adenine base, the therapy restores the gene sequence to its functional M-AAT state.
Post-treatment analysis revealed a rapid physiological response. The patient’s serum AAT concentration climbed from a baseline of 0.15 g/L to 0.70 g/L by the ten-week mark. Subsequent testing of the patient’s purified AAT confirmed it possessed anti-elastase activity comparable to the healthy M-AAT control, suggesting the corrected protein is functionally equivalent to the wild-type version.
Liver Biopsy Reveals Mild Inflammation and Safe Recovery
Researchers from Hannover Medical School and Shanghai Jiao Tong University conducted a liver biopsy to assess the localized impact of the gene correction. The histology revealed sparse AAT polymer deposits alongside mild portal inflammation and fibrosis. Because no pretreatment biopsy was available for this specific patient, the researchers noted that they could not definitively quantify the regression of pre-existing liver pathology. However, the procedure demonstrated a favorable short-term safety profile; mild transaminase elevations were observed but resolved spontaneously by day 14.
The study also addressed concerns regarding genomic fidelity. Sequencing of candidate off-target sites indicated no detectable bystander edits or unintended genetic alterations.
Disclaimer: The Info
While the current results are promising, the study investigators emphasized that larger cohorts and extended follow-up periods are necessary to confirm long-term durability and safety.
The current data set moves gene correction forward from laboratory models to clinical application. As the medical community assesses these results, the focus shifts toward identifying the optimal patient population for Phase II and Phase III trials. Determining whether this therapy can halt or reverse established liver fibrosis remains the primary objective for upcoming longitudinal studies.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.